BiomX Inc.

BiomX Inc. (NYSE American: PHGE) is a clinical-stage biopharmaceutical company that became publicly traded in 2019 following a merger with CHAC Inc., a special purpose acquisition company. The company operates in the biotechnology sector, focusing on the research and development of phage-based therapies designed to target and destroy harmful bacteria. BiomX filed this Form 8-K current report with the SEC on March 6, 2024, disclosing a material event in the ordinary course of its post-merger public reporting obligations. The company continues to advance its clinical pipeline within the infectious disease and microbiome space. Visit SpacDesk and sign up for full data, filings, and analytics on BiomX and hundreds of other SPAC-originated companies.